Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis must boost Menveo trial

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Novartis must add 1,500 pediatric patients to its safety database for Menveo before FDA will approve the meningococcal meningitis vaccine for use before age 11. The firm filed a BLA for Menveo (MenACWY-CRM) in August 2008 for ages 11-55, targeting four strains of meningococcal meningitis: A, C, W-135 and Y. An ongoing Phase III program is evaluating the vaccine in infants and children two months to 10 years old, and it is this program that the agency said was not powered for its endpoints. During a Jan. 28 earnings call, Novartis Vaccines and Diagnostics CEO Andrin Oswald said "this reflects a safety standard that FDA has now made us aware of, and it had not been discussed in previous discussions before we started the Phase III." The firm has been in discussion with FDA on the Menveo outcome for "quite a while, he added. "It was unfortunate that the request came up so late." Gathering the additional data will push a U.S. filing for the pediatric population to 2011, although a European filing is still planned for 2010, the firm said. Menveo is key to Novartis' blockbuster vaccine strategy 1(Pharmaceutical Approvals Monthly May 2008, p. 18)
Advertisement

Related Content

Menveo Beats Menactra In Teen Meningitis Phase III Trial

Topics

Advertisement
UsernamePublicRestriction

Register

PS004072

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel